Ferric citrate controls phosphorus and delivers iron in patients on dialysis

Journal of the American Society of Nephrology

Volumn 26, Issue 2, 2015, Pages 493-503

  Lewis, Julia B ^a   Sika, Mohammed ^a   Koury, Mark J ^a   Chuang, Peale ^b   Schulman, Gerald ^a   Smith, Mark T ^c   Whittier, Frederick C ^d   Linfert, Douglas R ^e   Galphin, Claude M ^f   Athreya, Balaji P ^g   Nossuli, A Kaldun Kaldun ^h   Chang, Ingrid J ⁱ   Blumenthal, Samuel S ^j   Manley, John ^k   Zeig, Steven ^l   Kant, Kotagal S ^m   Olivero, Juan Jose ⁿ   Greene, Tom ^o   Dwyer, Jamie P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Metrolina Nephrology Associates   (United States)

^c Kidney Care Associates   (United States)

^d Clinical Research Ltd   (United States)

^e Nephrology Associates   (United States)

^f Southeastern Renal Research Institute   (United States)

^g Pioneer Valley Nephrology   (United States)

^h Washington Nephrology Associates   (United States)

ⁱ Western Nephrology   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k Mountain Kidney and Hypertension Inc   (United States)

^l Pines Care Research Center   (United States)

^m UNIVERSITY OF CINCINNATI   (United States)

ⁿ Kidney Institute of Houston   (United States)

^o UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ANTIANEMIC AGENT; BICARBONATE; CALCIUM ACETATE; FERRIC CITRATE; FERRITIN; HEMOGLOBIN; IRON; PHOSPHORUS; PLACEBO; SEVELAMER CARBONATE; TRANSFERRIN; FERRIC ION;

ADULT; ALUMINUM BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CONTROLLED STUDY; END STAGE RENAL DISEASE; ERYTHROCYTE COUNT; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; IRON STORAGE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TRANSFERRIN BLOOD LEVEL; TREATMENT FAILURE; ANEMIA, IRON-DEFICIENCY; CLINICAL TRIAL; DOSE RESPONSE; ISRAEL; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; UNITED STATES;

ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; IRON; ISRAEL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHORUS; RENAL DIALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84924004431     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014020212     Document Type: Article

References (34)

1. Delmez JA, Slatopolsky E: Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317, 1992
2. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA: Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 20: 397-404, 2009
3. Umanath K, Blumenthal SS, Koury M, Sika M, Greco BA, Jalal DI, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Lewis JB, Dwyer JP, for the Collaborative Study Group: Ferric citrate as a phosphate binder reduces IV iron and erythropoiesis stimulating agent (ESA) use. Presented at the American Society of Nephrology Kidney Week, Atlanta, GA, November 7, 2013
4. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB; Collaborative Study Group: Dose-response and ef ficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: A short-term randomized trial. Am J Kidney Dis 61: 759-766, 2013
5. Hsu CH, Patel SR, Young EW: New phosphate binding agents: Ferric compounds. J Am Soc Nephrol 10: 1274-1280, 1999
6. Sika M, Koury M, Smith M, Greene T, Sinsakul MV, Korbet S, Lewis JB, for the Collaborative Study Group: Evaluation of ferric citrate as a phosphate binder in dialysis patients requiring high doses of phosphate binders. Presented at the American Society of Nephrology Renal Week, San Diego, CA, October 29, 2009
7. Sika M, Sinsakul MV, Niecestro RM, Chiang S: Prolonged use of ferric citrate (FC) as a phosphate binder reduces IV iron use in patients with ESRD. Presented at the American Society of Nephrology Renal Week, Denver, CO, November 20, 2010
8. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J; Collaborative Study Group: The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 121: c25-c29, 2012
9. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP; Collaborative Study Group: Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int 17: 67-74, 2013
10. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH: An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Trasplant 17: 265-270, 2002
11. Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y: Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: Results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 36: 478-487, 2012
12. Molony DA, Murthy B: Accumulation of metals and minerals from phosphate binders. Blood Purif 23[Suppl 1]: 2-11, 2005
13. Finn WF; SPD 405-307 Lanthanum Study Group: Lanthanumcarbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65: 191-202, 2006
14. Fresenius Medical Care North America: PhosLo (Package Insert), Waltham, MA, Fresenius Medical Care North America, 2007
15. Genzyme Corporation: Renvela (Package Insert). Cambridge, MA, Genzyme Corporation, 2010
16. Shire US Inc.: Fosrenol (Package Insert). Wayne, PA, Shire US Inc., 2012
17. Moriniere P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine C, Marie A, Leflon P, Roche D, Fournier A: Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: Lack of deleterious effect on bone mineralisation. Nephrol Dial Trasplant 3: 651-656, 1988
18. Sevelamer reduces the efficacy of many other drugs. Prescrire Int 18: 164-165, 2009
19. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl JMed 362: 1312-1324, 2010
20. Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD: Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 135: 452-458, 2000
21. Sargent JA, Acchiardo SR: Iron requirements in hemodialysis. Blood Purif 22: 112-123, 2004
22. Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR: Intravenous iron versus erythropoiesis-stimulating agents: Friends or foes in treating chronic kidney disease anemia? Adv Chronic Kidney Dis 16: 143-151, 2009
23. Besarab A, Coyne DW: Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 6: 699-710, 2010
24. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998
25. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996
26. Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM: The DOPPS practice monitor for US dialysis care: Trends through December 2011. Am J Kidney Dis 61: 342-346, 2013
27. Rambod M, Kovesdy CP, Kalantar-Zadeh K: Combined high serum ferritin and low iron saturation in hemodialysis patients: The role of inflammation. Clin J Am Soc Nephrol 3: 1691-1701, 2008
28. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372-379, 2008
29. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group: Ferric gluconate is highly ef ficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients ' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975-984, 2007
30. Rodby R, Umanath K, Hsieh A, Niecestro R, Lewis J, Dwyer J: Phosphorus binding with ferric citrate reduces erythropoiesis-stimulating agent (ESA) and IV iron usage and cost in patients with ESRD. Presented at the National Kidney Foundation Spring Clinical Meetings, Las Vegas, NV, April 23, 2014
31. Bansal A, Sandhu G, Gupta I, Kalahalli S, Nayak R, Zouain E, Chitale RA, Meisels I, Chan G: Effect of aggressively driven intravenous iron therapy on infectious complications inend-stagerenal diseasepatientsonmaintenance hemodialysis [published online ahead of print July 23, 2012]. Am J Ther
32. USRDS: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
33. Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 366: 348-359, 2012
34. Dmitrienko A, Offen WW, Westfall PH: Gatekeeping strategies for clinical trials that do not require all primary effects to be significant. Stat Med 22: 2387-2400, 2003